312 related articles for article (PubMed ID: 26580879)
41. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
[TBL] [Abstract][Full Text] [Related]
42. [Treatment of crow's feet with two different botulinum toxin type A preparations in split-face technique].
Prager W; Wissmüller E; Kollhorst B; Böer A; Zschocke I
Hautarzt; 2011 May; 62(5):375-9. PubMed ID: 21503782
[TBL] [Abstract][Full Text] [Related]
43. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study.
Flynn TC; Carruthers JA; Carruthers JA; Clark RE
Dermatol Surg; 2003 Sep; 29(9):943-50; discussion 950-1. PubMed ID: 12930337
[TBL] [Abstract][Full Text] [Related]
44. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
45. Aesthetic ONE21 Technique for Injecting IncobotulinumtoxinA into the Forehead: Initial Experience With 86 Patients.
de Sanctis Pecora C; Bussamara Pinheiro MV; Figueiredo V; Guerra R
J Drugs Dermatol; 2021 Jan; 20(1):31-37. PubMed ID: 33400422
[TBL] [Abstract][Full Text] [Related]
46. Sixth nerve palsy following botulinum toxin injection for facial rejuvenation.
Dolar Bilge A; Sadigov F; Salar-Gomceli S
Cutan Ocul Toxicol; 2017 Jun; 36(2):193-194. PubMed ID: 27558865
[TBL] [Abstract][Full Text] [Related]
47. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA.
Nettar KD; Yu KC; Bapna S; Boscardin J; Maas CS
Arch Facial Plast Surg; 2011; 13(6):380-6. PubMed ID: 21690460
[TBL] [Abstract][Full Text] [Related]
48. Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
Shome D; Kapoor R; Khare S
J Cosmet Dermatol; 2019 Dec; 18(6):1635-1641. PubMed ID: 31135088
[TBL] [Abstract][Full Text] [Related]
49. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
[TBL] [Abstract][Full Text] [Related]
50. Botulinum toxin A: a 9-month clinical and 3D in vivo profilometric crow's feet wrinkle formation study.
Levy JL; Servant JJ; Jouve E
J Cosmet Laser Ther; 2004 May; 6(1):16-20. PubMed ID: 15370408
[TBL] [Abstract][Full Text] [Related]
51. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
Grosset DG; Tyrrell EG; Grosset KA
J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
[TBL] [Abstract][Full Text] [Related]
52. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
[TBL] [Abstract][Full Text] [Related]
53. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.
Allen SB; Goldenberg NA
Dermatol Surg; 2012 Jun; 38(6):867-70. PubMed ID: 22268727
[TBL] [Abstract][Full Text] [Related]
54. A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.
Wilson AJ; Chang B; Taglienti AJ; Chin BC; Chang CS; Folsom N; Percec I
Plast Reconstr Surg; 2016 May; 137(5):1424-1433. PubMed ID: 27119918
[TBL] [Abstract][Full Text] [Related]
55. Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial.
Zimbler MS; Holds JB; Kokoska MS; Glaser DA; Prendiville S; Hollenbeak CS; Thomas JR
Arch Facial Plast Surg; 2001; 3(3):165-9. PubMed ID: 11497500
[TBL] [Abstract][Full Text] [Related]
56. Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial.
Hexsel D; Hexsel C; Siega C; Schilling-Souza J; Rotta FT; Rodrigues TC
JAMA Dermatol; 2013 Dec; 149(12):1386-91. PubMed ID: 24108521
[TBL] [Abstract][Full Text] [Related]
57. The effect of full-face broadband light treatments alone and in combination with bilateral crow's feet Botulinum toxin type A chemodenervation.
Carruthers J; Carruthers A
Dermatol Surg; 2004 Mar; 30(3):355-66; discussion 366. PubMed ID: 15008861
[TBL] [Abstract][Full Text] [Related]
58. OnabotulinumtoxinA for Treatment of Moderate to Severe Crow's Feet Lines: A Review.
Carruthers A; Bruce S; Cox SE; Kane MA; Lee E; Gallagher CJ
Aesthet Surg J; 2016 May; 36(5):591-7. PubMed ID: 26979457
[TBL] [Abstract][Full Text] [Related]
59. Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.
Arat YO; Yen MT
Ophthalmic Plast Reconstr Surg; 2007; 23(1):22-4. PubMed ID: 17237684
[TBL] [Abstract][Full Text] [Related]
60. A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study.
Narurkar VA; Cohen JL; Dayan S; Kaminer MS; Rivkin A; Shamban A; Sykes JM; Teller CF; Weinkle SH; Werschler WP; Drinkwater A; Pucci ML; Gallagher CJ
Dermatol Surg; 2016 May; 42 Suppl 2():S177-91. PubMed ID: 27128246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
